US 8754046
MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1
granted A61KA61K2039/53A61K2239/31
Quick answer
US patent 8754046 (MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2039/53, A61K2239/31, A61K2239/38, A61K35/17